| News
Lyfegen collaborating with Johnson & Johnson
03.08.2021
The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result in cost-savings. Lyfegen teamed up with Johnson & Johnson for the implementation.

Girisha Fernando, Frederico Braga, Michel Mohler and Nico Mros from Lyfegen HealthTech AG (img: Lyfegen)
The concept of value-based healthcare is rooted in the definition of patient outcome per franc spent. By aligning all processes with this approach, the aim is to improve patient outcomes and reduce healthcare costs at the same time. Founded in 2018, the Basel-based company Lyfegen has developed a platform that can be used to implement value-based healthcare processes. Lyfegen teamed up with the life sciences company Johnson & Johnson Switzerland and a “leading” Swiss hospital for the implementation process, which has now been brought to a close, further details of which can be found in a press release.
The patented Lyfegen platform automates the collection and analysis of all patient-related data. In this way, the aim is to achieve transparency with regard to the contract content, expenses and healthcare outcomes. Lyfegen describes the platform as a “blueprint” from which global hospitals, health insurance companies and life sciences providers all stand to benefit. “Covid-19 has shown us the urgent need for a more sustainable healthcare system”, comments Girisha Fernando, CEO of Lyfegen, in the press release. “With the implementation of value-based healthcare agreements on the Lyfegen platform, we are extremely proud to help Johnson & Johnson and hospitals to accelerate the transition to value-based healthcare and improve patient health outcomes at reduced cost”.
For Lyfegen, the agreed partnership represents a key “milestone”, the press release explains further. The Basel-based startup recently opened up a new investment round.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
BeiGene opens European headquarters in Basel
BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...
Read MoreThe 25 Best AI Courses in the Basel Area, Germany and France
Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...
Read MoreEngimmune Therapeutics banks 15.5 million Swiss francs
Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...
Read MoreBionter receives 3 million US dollars in investments
Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...
Read MoreResistell seeking to further develop test to combat antibiotic resistance
The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...
Read MoreBiotech startup Cimeio receives 46 million Swiss francs for cell therapy
Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...
Read More